These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 8935599)

  • 1. Somatostatin analogue treatment of neuroendocrine tumours.
    de Herder WW; van der Lely AJ; Lamberts SW
    Postgrad Med J; 1996 Jul; 72(849):403-8. PubMed ID: 8935599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin receptors: clinical implications for endocrinology and oncology.
    Lamberts SW; de Herder WW; van Koetsveld PM; Koper JW; van der Lely AJ; Visser-Wisselaar HA; Hofland LJ
    Ciba Found Symp; 1995; 190():222-36; discussion 236-9. PubMed ID: 7587649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin analogues: treatment of pituitary and neuroendocrine tumors.
    Colao A; Faggiano A; Pivonello R
    Prog Brain Res; 2010; 182():281-94. PubMed ID: 20541670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
    Öberg K; Lamberts SW
    Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of somatostatin analogue therapy.
    Stewart PM; James RA
    Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Oct; 13(3):409-18. PubMed ID: 10909432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
    Oberg K
    Ann Oncol; 2001; 12 Suppl 2():S111-4. PubMed ID: 11762335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
    Arnold R; Simon B; Wied M
    Digestion; 2000; 62 Suppl 1():84-91. PubMed ID: 10940693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of somatostatin analogues in the treatment of neuroendocrine tumours based on the results of recent clinical trials].
    Igaz P
    Orv Hetil; 2014 Nov; 155(48):1908-12. PubMed ID: 25417137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
    Kaltsas GA; Papadogias D; Makras P; Grossman AB
    Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy.
    Lamberts SW; Hofland LJ; de Herder WW; Kwekkeboom DJ; Reubi JC; Krenning EP
    Front Neuroendocrinol; 1993 Jan; 14(1):27-55. PubMed ID: 8097480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a role for somatostatin and its analogs in Cushing's syndrome?
    de Herder WW; Lamberts SW
    Metabolism; 1996 Aug; 45(8 Suppl 1):83-5. PubMed ID: 8769391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses.
    de Herder WW; Lamberts SW
    Curr Opin Oncol; 2002 Jan; 14(1):53-7. PubMed ID: 11790981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors.
    Feelders RA; de Herder WW; Neggers SJ; van der Lely AJ; Hofland LJ
    Drugs Today (Barc); 2013 Feb; 49(2):89-103. PubMed ID: 23462624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
    Shi W; Buchanan KD; Johnston CF; Larkin C; Ong YL; Ferguson R; Laird J
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of pituitary tumors: somatostatin.
    Tichomirowa MA; Daly AF; Beckers A
    Endocrine; 2005 Oct; 28(1):93-100. PubMed ID: 16311415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.
    Aparicio T; Ducreux M; Baudin E; Sabourin JC; De Baere T; Mitry E; Schlumberger M; Rougier P
    Eur J Cancer; 2001 May; 37(8):1014-9. PubMed ID: 11334727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic use of somatostatin analogues in endocrinology].
    Faglia G; Arosio M
    Recenti Prog Med; 1992 Nov; 83(11):626-33. PubMed ID: 1363150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
    Shimon I; Yan X; Taylor JE; Weiss MH; Culler MD; Melmed S
    J Clin Invest; 1997 Nov; 100(9):2386-92. PubMed ID: 9410919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.
    Chan DL; Ferone D; Albertelli M; Pavlakis N; Segelov E; Singh S
    Endocrine; 2017 Sep; 57(3):366-375. PubMed ID: 28726183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
    Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
    Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.